Search results
Calliditas Therapeutics stock target lifted on strong sales By Investing.com
Investing.com· 1 day agoOn Thursday, Jefferies, a global investment banking firm, raised the stock price target for...
ORPHAN Cures | Pacific Sun
Pacific Sun· 2 days agoFor the roughly 30 million Americans living with a rare disease, the chances of finding an effective treatment are tragically slim. Adding insult to illness, an element of 2022’s Inflation Reduction ...
Calliditas Q1 report, January - March 2024
WTRF Wheeling· 2 days agoNet sales amounted to SEK 295.5 million, of which TARPEYO® net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the three months ended March 31, 2023, net ...
Adolore BioTherapeutics Outlines Strategy for its Next Generation, Disease-Modifying, Non-Opioid...
Morningstar· 3 days agoDELRAY BEACH, FL / ACCESSWIRE / May 21, 2024 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments ...
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual...
Digital Journal· 3 days agoMedicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it ...
FDA grants Cartesian Therapeutics RMAT status for MG therapy By Investing.com
Investing.com· 2 days agoCartesian Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food...
Earnings call: Longeveron reports Q1 2024 results, optimistic on Lomecel-B
Investing.com· 7 days agoLongeveron Inc. (LGVN), a leader in regenerative medicine, recently discussed its first-quarter...
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and...
Morningstar· 6 days agoInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis - 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
WTNH-TV New Haven· 1 day agoKazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with ...
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent...
FOX21 Colorado Springs· 1 day agoPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company ...